

# Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/103187/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Abraham, Jacinta and Staffurth, John Nicholas ORCID: <https://orcid.org/0000-0002-7834-3172> 2016. Hormonal therapy for cancer. *Medicine* 44 (1) , pp. 30-33. 10.1016/j.mpmed.2015.10.014 file

Publishers page: <http://dx.doi.org/10.1016/j.mpmed.2015.10.014>  
<<http://dx.doi.org/10.1016/j.mpmed.2015.10.014>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.

See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Hormonal therapy for cancer

**Jacinta Abraham**

**John Staffurth**

**Jacinta Abraham BMedSci BMBS MRCP FRCR** is a Consultant Clinical Oncologist and the Clinical Director at Velindre Cancer Centre, Cardiff, UK. She qualified from Nottingham Medical School in 1990. She specializes in breast cancer and has research interests in bisphosphonates, infertility in cancer and secondary breast cancer. Competing interests: none declared.

**John Staffurth MBBS MD MRCP FRCR** is a Clinical Reader in Oncology at Cardiff University, and a Consultant Clinical Oncologist at Velindre Cancer Centre, Cardiff, UK. He qualified from Guy's Hospital, London University, UK in 1992. His research interests include prostate and bladder cancer, and radiotherapy. Competing interests: none declared.

## **Abstract**

Hormone therapy is an effective and non-toxic therapy for oestrogen and progesterone receptor-positive breast cancer and prostate cancer. Serum levels of oestradiol and testosterone are controlled by the hypothalamic–pituitary–gonadal pathway. Oestradiol is produced in premenopausal women from the ovaries and in postmenopausal women by peripheral conversion of adrenal androgens by aromatase. In premenopausal women with breast cancer and men with prostate cancer, treatment is primarily achieved by castration. In postmenopausal women selective oestrogen receptor modulators (e.g. tamoxifen) or aromatase inhibitors are used. Hormone therapy can be used to reduce the size of the primary cancer prior to radical surgery or radiotherapy or to reduce the risk of recurrence. Hormone therapy is highly effective in patients with locally advanced or metastatic disease, with a high response rate. Most patients eventually relapse with ‘castrate-refractory’ disease, for which increasing numbers of active agents are entering clinical practice.

**Keywords:** Androgen deprivation therapy; anti-androgens; aromatase inhibitors; breast cancer; hormone therapy; prostate cancer; selective oestrogen receptor modulators

## **Aetiology**

This paper will concentrate on the management of breast and prostate cancers in which the impact of hormone therapy is most clinically significant. Increased exposure to endogenous or exogenous oestrogens may be linked to the development of breast cancer (Table 1). However, there is no evidence that exposure to androgens is important in the development of prostate cancer.

## **Historical evidence**

In 1896 Beatson demonstrated that surgical oophorectomy resulted in tumour regression in premenopausal women with metastatic breast cancer. Charles Huggins was awarded the Nobel Prize for medicine in 1966 following his discovery that surgical orchidectomy was a successful treatment for metastatic prostate cancer.

## Hormone synthesis

Oestrogen is synthesized from cholesterol in the parafollicular ovaries in premenopausal women via the hypothalamic–pituitary–gonadal axis (Figure 1), and in the adrenals in postmenopausal women. In premenopausal women, oestrogen production is cyclical: gonadotrophin-releasing hormone (GnRH) is released from the hypothalamus with a circadian rhythm under direct feedback by circulating hormones. GnRH reacts with anterior pituitary receptors, leading to the release of luteinizing and follicle-stimulating hormone; these stimulate the ovaries to produce oestradiol.

In postmenopausal women, the main site of oestrogen synthesis is adipose tissue. Here, adrenal androgens (e.g. androstenedione) are converted from aromatase to oestrone. Oestrone is then converted to oestradiol by 17 $\beta$ -OH dehydrogenase. Postmenopausal synthesis varies depending on environmental and genetic factors (e.g. obesity).

In men, the main circulating androgen is testosterone, 90% of which is produced by the testicular Leydig cells under control of the hypothalamic–pituitary axis, as above.

The remaining circulating androgens (e.g. dihydroxyandrostenedione) are produced in the adrenal cortex from cholesterol. Testosterone is metabolized by 5 $\alpha$ -reductase within the prostate to the more biologically active dihydrotestosterone, which acts as the ligand for the androgen receptor (AR).

## Hormone receptors

In breast cancer, approximately 80% of postmenopausal women and 50% of premenopausal women have hormone receptor-positive disease. The degree of positivity is defined by the level of expression of both oestrogen (ER) and progesterone receptors, which are routinely measured immunohistochemically in newly diagnosed cases. Systemic treatment and, to some extent, prognosis is guided by hormone receptor status.

In contrast, measurement of ARs is not currently routinely performed in prostate cancer – it has no therapeutic or prognostic value because both hormone-dependent and ‘castrate-refractory’ prostate cancers (CRPCs) possess functioning ARs. Recent work suggests that AR variants may underlie resistance to castration.<sup>1</sup>

## Hormone therapy in breast cancer

### Ovarian ablation

In premenopausal women oestrogen suppression is achieved by chemical ablation, radiation to the ovaries or surgical oophorectomy. Chemical ablation is reversible and achieved by using a GnRH agonist (GnRH $\alpha$  or LHRH $\alpha$ ) such as goserelin, usually as a monthly depot injection.

### Other hormonal agents in breast cancer

An increasing number of hormonal treatment options are available to treat breast cancer. A description of the different licensed drugs is given in Table 2. The most commonly used treatments include tamoxifen and aromatase inhibitors (AIs).

**Tamoxifen:** this is a selective oestrogen receptor modulator with complex actions on ERs, acting predominantly as an antagonist, with a weak agonist effects. In ER-positive early breast cancer, 5 years of tamoxifen after surgery reduces the annual recurrence rate by 41% and annual mortality rate by 34%.<sup>2</sup> There is evidence of a reduction in breast cancer recurrence and mortality by continuing tamoxifen in ER-positive disease for 10 years rather than stopping at 5 years.<sup>3</sup>

Tamoxifen may be used in premenopausal and postmenopausal women. The main adverse effects are hot flushes, night sweats and vaginal discharge. There is an increased risk of thrombotic events. Vaginal bleeding should be promptly evaluated because of the increased risk of endometrial cancer.<sup>4</sup>

**Aromatase inhibitors:** several Phase III clinical trials have established third-generation AIs as the new gold standard in the adjuvant hormonal treatment of receptor-positive early breast cancer. They are contraindicated in premenopausal women unless ovarian suppression has been induced. There are three main approaches with early breast cancer:

- up-front use for 5 years
- planned or unplanned switching, i.e. use of AIs for 2–3 years after 2–3 years of tamoxifen
- extended therapy, i.e. after 5 years' use of tamoxifen.

The main toxicities of AIs are hot flushes, arthralgia, reduced bone mineral density and increased risk of fractures. Women at risk of osteoporosis should be carefully monitored or treated with bisphosphonates where necessary.<sup>5</sup>

A new approach is the use of AIs in combination with signal transduction or pathway inhibitors. Everolimus is an mTOR inhibitor licensed for use in combination with exemestane in the metastatic setting.<sup>6</sup>

### **Main indications for hormonal therapy in breast cancer**

- As a neoadjuvant to reduce the size of the primary tumour, making it operable or reducing the extent of surgery, for example from mastectomy to wide local excision
- As an adjuvant after surgery to reduce the risk of recurrence and improve survival
- As a palliative treatment to shrink and control large inoperable cancers
- As a palliative treatment for metastatic disease to prolong and improve quality of life.

### **Hormone therapy in prostate cancer**

#### **Androgen deprivation therapy (ADT)**

Serum testosterone is reduced to castrate levels by surgical or chemical castration, using LHRHa or the newer LHRH antagonists. Castration can lead to hot flushes, sweats and reduced libido. Patients may notice reduced muscle mass, reduced strength and weight gain. There can be loss of bone mineral density and there are concerns of an increased risk of fatal cardiac events.

Initial use of LHRHa results in a surge in serum testosterone, which may worsen symptoms: all patients should take oral antiandrogens for at least 3 weeks, starting 1–2 weeks prior to initial LHRHa injection. This is not needed with LHRH antagonists, which are preferred in emergency situations.

#### **Other hormonal agents in prostate cancer**

The hormonal agents commonly used in the management of CRPC are described in Table 3.

Bicalutamide is a non-steroidal antiandrogen and competitive AR inhibitor that is often used as the initial agent for CRPC, with a response rate up to 66%. Single-agent bicalutamide (at a dose of 150 mg daily) can be used as an alternative to ADT in some clinical situations. There is a lower incidence of erectile dysfunction but equivalent efficacy has not been proven.

Degarelix is an LHRH antagonist and does not cause a testosterone flare. It rapidly achieves castrate levels of testosterone and can be used in emergency situations such as new diagnoses presenting with cord compression.

Abiraterone acetate and enzalutamide are newer agents causing much greater AR suppression, through different mechanisms; they have been shown to prolong survival both before and after docetaxel chemotherapy.<sup>7–10</sup>

Corticosteroids are highly active in CRPC but have no proven survival advantage. Long-term use is associated with typical glucocorticoid adverse effects, such as proximal myopathy and reduced bone mineral density, and patients require regular review.

### **Main indications for hormonal treatment in prostate cancer**

- As a neoadjuvant prior to radiotherapy to improve local and biochemical (prostate-specific antigen) control in patients with locally advanced tumours
- As an adjuvant following radiotherapy to improve overall survival in high-risk disease
- Palliatively for metastatic or recurrent prostate cancer. Almost 100% of patients respond, with a median duration of response of 12 months.

### **Hormone resistance**

Resistance develops in nearly all patients with metastatic breast and prostate cancer who initially respond to hormone therapy, resulting in disease progression. The molecular causes of resistance are complex, varied and not well understood. Mechanisms may include increased sensitivity of hormone receptors, pathway activation without exposure to hormones (constitutive activation) or up-regulated downstream survival pathways. As these become better characterized, new agents can be developed and trialled.

**Table 1**

**Hormonal risks for breast cancer**

**Risk factors**

Early menarche  
Late menopause  
Nulliparity  
Obesity  
Hormone replacement therapy

**Protective factors**

Breast-feeding  
Young age at full-term pregnancy

**Table 2****Hormonal therapies in breast cancer**

<b>Drug</b>	<b>Type</b>	<b>Dose/route</b>	<b>Mode of action</b>
Tamoxifen	Anti-oestrogen	20 mg daily p.o.	Competes with oestradiol for ER binding
Anastrozole	Non-steroidal aromatase inhibitor	1 mg daily p.o.	Competitive aromatase inhibition
Letrozole	Non-steroidal aromatase inhibitor	2.5 mg daily p.o.	Competitive aromatase inhibition
Exemestane	Steroidal aromatase inhibitor	25 mg daily p.o.	Irreversible aromatase inhibition
Fulvestrant	Oestrogen receptor antagonist	250 mg monthly i.m.	Down-regulation of the ER protein
Megestrol acetate	Progestin	80–160 mg daily p.o.	Cellular action not fully understood Down-regulation of ovarian steroidogenesis

ER, oestrogen receptor; i.m., intramuscular; p.o., oral.

**Table 3**  
**Hormonal therapies in prostate cancer**

Drug	Type	Dose/route	Mode of action
Goserelin	LHRH agonist	3.6 mg every 28 days or 10.8 mg every 3 months s.c.	Reduced pituitary production of LH and FSH
Leuporelin	LHRH agonist	3.75 mg every 28 days or 11.25 mg every 3 months – s.c./i.m.	Reduced pituitary production of LH and FSH
Degarelix	LHRH antagonist	240 mg then 80 mg every 28 days s.c.	Reduced pituitary production of LH and FSH
Bicalutamide	Non-steroidal antiandrogen	50 mg (combination dose) or 150 mg (single agent) daily p.o.	Competitive AR inhibition
Prednisolone	Corticosteroid	5–10 mg daily p.o.	Adrenal suppression
Dexamethasone	Corticosteroid	0.5–2 mg daily p.o.	Adrenal suppression
Abiraterone acetate	Androgen synthesis inhibitor	1000 mg daily p.o. with prednisolone 5 mg twice daily p.o.	Reduced androgen production within adrenal glands and prostate cancer cells
Enzalutamide	AR inhibitor	160 mg daily p.o.	Competitive AR inhibition, block of AR translocation to the nucleus

AR, androgen receptor; FSH, follicle-stimulating hormone; i.m., intramuscular; LH, luteinizing hormone; LHRH, luteinizing hormone-releasing hormone; p.o., oral; s.c., subcutaneous.



## The hypothalamic-pituitary-gonadal axis




Figure 1

## References

- 1 Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. *N Engl J Med*. 2014; **371**: 1028–38.
- 2 Early Breast Cancer Trialists' Collaborative Group (EBCTC G). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005; **365**: 1687–717.
- 3 Davies C, Pan H, Godwin, et al; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor positive breast cancer: ATLAS, a randomised trial. *Lancet* 2012; **381**: 805–16.
- 4 Saadat M, Truong PT, Kader HA, et al. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer: comparison of cohorts treated with and without tamoxifen. *Cancer* 2007; **110**: 31–7.
- 5 Royal College of Physicians, the Bone and Tooth Society, the National Osteoporosis Society. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London: RCP, 2002.
- 6 Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med* 2012; **366**: 520–9.
- 7 Fizazi K, Scher HI, Molina A, et al.; COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncol* 2012; **13**: 983–92.
- 8 Ryan CJ, Smith MR, Fizazi K, et al.; COU-AA-302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncol* 2015; **16**: 152–60.
- 9 Beer TM, Armstrong AJ, Rathkopf DE; PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med* 2014; **371**: 424–33.
- 10 Scher HI, Fizazi K, Saad F, Taplin ME, et al.; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med* 2012; **367**: 1187–97.

**What's new**

- The mechanisms behind resistance to hormonal therapies are being better characterized
- New drugs targeting these mechanisms have shown a survival advantage over previous best care and have entered routine practice
- Further agents overcoming resistance to these newer agents are now being studied
- In breast cancer, pathway inhibitors are used in combination with aromatase inhibitors to overcome resistance
- In prostate cancer these are abiraterone acetate and enzalutamide